A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Latest Information Update: 10 Aug 2023
At a glance
- Drugs GRN 1201 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors BrightPath Biotherapeutics
- 05 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 10 Jun 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Mar 2023.
- 10 Jun 2022 Status changed from recruiting to active, no longer recruiting.